Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 48: 601-603, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (20)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ma, J.
Right arrow Articles by Stampfer, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ma, J.
Right arrow Articles by Stampfer, M. J.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
(Clinical Chemistry. 2002;48:601-603.)
© 2002 American Association for Clinical Chemistry, Inc.


Editorial

Body Iron Stores and Coronary Heart Disease

Jing Ma1a and Meir J. Stampfer1,2

1 Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115

2 Departments of Epidemiology and Nutrition, Harvard School of Public Health, Boston, MA 02115

aAuthor for correspondence. Fax 617-525-2008; e-mail jing.ma@channing.harvard.edu.

Over the past 20 years, the hypothesis that body iron stores are associated with risk of coronary heart disease (CHD) has generated extensive debate (1)(2)(3)(4). This debate has intensified in the last 4 years after reports from three studies that carriers of the recently discovered HFE C282Y mutation commonly seen in hereditary hemochromatosis have significantly increased risk of CHD (5)(6)(7)(8)(9). Clinical trial has recently been proposed as the ultimate resolution to assess protective effects of iron depletion against CHD among C282Y heterozygotes (9). In this issue of Clinical Chemistry, Bozzini et al. (10) show that neither a biochemical marker (serum ferritin) nor a genetic marker (C282Y carrier status) of body iron stores was significantly associated with angiographically documented coronary atherosclerosis.

Do increased body iron stores increase risk of CHD? Are individuals who are heterozygotes for the common C282Y mutation at especially high risk of CHD? Can iron depletion reduce the risk? These questions have important implications given the common practice of fortification of food and supplements with iron in industrialized countries and the high frequency of HFE C282Y carriers (~9% of them are of northern European descent) (11). Moreover, the "Oxidative Stress Theory" suggests that iron, as a potent catalytic agent, could promote formation of highly reactive oxygen species and lipid peroxidation, a crucial step in atherosclerosis (4). Thus, evaluation of the iron hypothesis for CHD will lead to advances in our understanding of its pathogenesis. To date, conflicting results have been reported from epidemiologic studies (4)(8)(9)(12)(13)(14) conducted in different countries and populations using different biochemical and genetic markers of . . . [Full Text of this Article]


Acknowledgments


References




The following articles in journals at HighWire Press have cited this article:


Home page
JAMAHome page
F. B. Hu
The Iron-Heart Hypothesis: Search for the Ironclad Evidence
JAMA, February 14, 2007; 297(6): 639 - 641.
[Full Text] [PDF]


Home page
CirculationHome page
D. L. van der A, J. J.M. Marx, D. E. Grobbee, M. H. Kamphuis, N. A. Georgiou, J. H. van Kats-Renaud, W. Breuer, Z. I. Cabantchik, M. Roest, H. A.M. Voorbij, et al.
Non-Transferrin-Bound Iron and Risk of Coronary Heart Disease in Postmenopausal Women
Circulation, April 25, 2006; 113(16): 1942 - 1949.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. Brea, D. Mosquera, E. Martin, A. Arizti, J. L. Cordero, and E. Ros
Nonalcoholic Fatty Liver Disease Is Associated With Carotid Atherosclerosis: A Case-Control Study
Arterioscler Thromb Vasc Biol, May 1, 2005; 25(5): 1045 - 1050.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
D.-H. Lee, A. R Folsom, and D. R Jacobs Jr
Iron, zinc, and alcohol consumption and mortality from cardiovascular diseases: the Iowa Women's Health Study
Am. J. Clinical Nutrition, April 1, 2005; 81(4): 787 - 791.
[Abstract] [Full Text] [PDF]


Home page
Br. J. Sports. Med.Home page
H Zotter, N Robinson, M Zorzoli, L Schattenberg, M Saugy, and P Mangin
Abnormally high serum ferritin levels among professional road cyclists
Br. J. Sports Med., December 1, 2004; 38(6): 704 - 708.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
R. Jiang, J. E. Manson, J. B. Meigs, J. Ma, N. Rifai, and F. B. Hu
Body Iron Stores in Relation to Risk of Type 2 Diabetes in Apparently Healthy Women
JAMA, February 11, 2004; 291(6): 711 - 717.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
J.-M. Liu, S. E Hankinson, M. J Stampfer, N. Rifai, W. C Willett, and J. Ma
Body iron stores and their determinants in healthy postmenopausal US women
Am. J. Clinical Nutrition, December 1, 2003; 78(6): 1160 - 1167.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
M. W. Knuiman, M. L. Divitini, J. K. Olynyk, D. J. Cullen, and H. C. Bartholomew
Serum Ferritin and Cardiovascular Disease: A 17-Year Follow-up Study in Busselton, Western Australia
Am. J. Epidemiol., July 15, 2003; 158(2): 144 - 149.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.